

# Ilke Sipahi

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1716248/ilke-sipahi-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

61

papers

4,788

citations

26

h-index

69

g-index

69

ext. papers

5,359

ext. citations

7.8

avg, IF

4.78

L-index

#	Paper	IF	Citations
61	Risk of cancer with angiotensin-receptor blockers increases with increasing cumulative exposure: Meta-regression analysis of randomized trials.. <i>PLoS ONE</i> , <b>2022</b> , 17, e0263461	3.7	1
60	Ankaferd blood stopper as a new strategy to avoid early complications after transradial procedures: A randomized clinical trial. <i>Journal of Interventional Cardiology</i> , <b>2018</b> , 31, 511-517	1.8	5
59	Comparison of Effects of Low- versus High-Dose Heparin on Access-Site Complications during Transradial Coronary Angiography: A Double-Blind Randomized Study. <i>Cardiology</i> , <b>2015</b> , 131, 142-8	1.6	13
58	Bypass grafting versus percutaneous intervention in multivessel coronary disease: the current state. <i>Current Cardiology Reports</i> , <b>2015</b> , 17, 7	4.2	2
57	Impact of QRS duration on survival benefit with prophylactic implantable cardioverter-defibrillators: a meta-analysis of randomized controlled trials. <i>Journal of Cardiovascular Medicine</i> , <b>2015</b> , 16, 811-6	1.9	1
56	A comparison of results of the US food and drug administration's mini-sentinel program with randomized clinical trials: the case of gastrointestinal tract bleeding with dabigatran. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 150-1	11.5	26
55	Coronary artery bypass grafting vs percutaneous coronary intervention and long-term mortality and morbidity in multivessel disease: meta-analysis of randomized clinical trials of the arterial grafting and stenting era. <i>JAMA Internal Medicine</i> , <b>2014</b> , 174, 223-30	11.5	157
54	Dabigatran's Real-world data about risk of myocardial infarction and gastrointestinal bleeding contradicts with randomized trials. <i>Journal of the American College of Cardiology</i> , <b>2013</b> , 62, 945-6	15.1	8
53	Echocardiography-guided or "sided" pericardiocentesis. <i>Echocardiography</i> , <b>2013</b> , 30, 997-1000	1.5	4
52	CRT should be reserved for a QRS duration $\geq$ 150 ms: pro. <i>Circulation: Arrhythmia and Electrophysiology</i> , <b>2013</b> , 6, 436-42	6.4	7
51	Reversal of severe biventricular dysfunction from cardiac hemochromatosis with iron removal. <i>Circulation: Heart Failure</i> , <b>2013</b> , 6, e14-5	7.6	5
50	Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. <i>Stroke</i> , <b>2012</b> , 43, 432-40	6.7	63
49	Effect of QRS morphology on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. <i>American Heart Journal</i> , <b>2012</b> , 163, 260-7.e3	4.9	185
48	Limitations of Subgroup Analyses in Meta-analysis of Cardiac Resynchronization Therapy by QRS Duration Reply. <i>Archives of Internal Medicine</i> , <b>2012</b> , 172, 375		
47	Treatment of heart failure with preserved ejection fraction: have we been pursuing the wrong paradigm?. <i>Mayo Clinic Proceedings</i> , <b>2011</b> , 86, 531-9	6.4	37
46	Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk. <i>American Journal of Cardiology</i> , <b>2011</b> , 108, 294-301	3	39
45	Impact of QRS duration on clinical event reduction with cardiac resynchronization therapy: meta-analysis of randomized controlled trials. <i>Archives of Internal Medicine</i> , <b>2011</b> , 171, 1454-62		200

44	Angiotensin-receptor blockade and risk of cancer: meta-analysis of randomised controlled trials. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 627-36	21.7	334
43	Angiotensin-receptor blockade, cancer, and concerns [AuthorsReply]. <i>Lancet Oncology, The</i> , <b>2010</b> , 11, 821-822	21.7	3
42	Successful combined use of Impella Recover 2.5 device and intra-aortic balloon pump support in cardiogenic shock from acute myocardial infarction. <i>ASAIO Journal</i> , <b>2010</b> , 56, 519-21	3.6	12
41	Low levels of low-density lipoprotein cholesterol and blood pressure and progression of coronary atherosclerosis. <i>Journal of the American College of Cardiology</i> , <b>2009</b> , 53, 1110-5	15.1	53
40	Pharmacological intervention trials <b>2009</b> , 103-110		
39	Effect of diabetes on progression of coronary atherosclerosis and arterial remodeling: a pooled analysis of 5 intravascular ultrasound trials. <i>Journal of the American College of Cardiology</i> , <b>2008</b> , 52, 255-62	15.1	235
38	Candidate mechanisms for regression of coronary atherosclerosis with high-dose statins: insight from intravascular ultrasonography trials. <i>American Journal of Cardiovascular Drugs</i> , <b>2008</b> , 8, 365-71	4	10
37	βBlockers and Progression of Coronary Atherosclerosis. <i>Annals of Internal Medicine</i> , <b>2008</b> , 148, 404	8	
36	Cardiac allograft vasculopathy: an update. <i>Heart Failure Clinics</i> , <b>2007</b> , 3, 87-95	3.3	17
35	Coronary artery calcification and changes in atheroma burden in response to established medical therapies. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 263-70	15.1	111
34	Rate of progression of coronary atherosclerotic plaque in women. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1546-51	15.1	63
33	Effects of Normal, Pre-Hypertensive, and Hypertensive Blood Pressure Levels on Progression of Coronary: Reply. <i>Journal of the American College of Cardiology</i> , <b>2007</b> , 49, 1369-1370	15.1	
32	Comparison of coronary atherosclerotic volume in patients with glomerular filtration rates $\geq 60$ ml/min/1.73 m <sup>2</sup> : a meta-analysis of intravascular ultrasound studies. <i>American Journal of Cardiology</i> , <b>2007</b> , 99, 813-6	3	28
31	Arterial remodelling: an independent pathophysiological component of atherosclerotic disease progression and regression. Insights from serial pharmacological intervention trials. <i>European Heart Journal</i> , <b>2007</b> , 28, 2299-300	9.5	3
30	Coronary artery wall enhances with intracoronary injection of echocontrast media during in vivo intravascular ultrasound. <i>European Journal of Echocardiography</i> , <b>2007</b> , 8, 234-6		1
29	Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. <i>JAMA - Journal of the American Medical Association</i> , <b>2007</b> , 297, 499-508	27.4	530
28	Beta-blockers and progression of coronary atherosclerosis: pooled analysis of 4 intravascular ultrasonography trials. <i>Annals of Internal Medicine</i> , <b>2007</b> , 147, 10-8	8	70
27	Coronary angiography for follow-up of heart transplant recipients: insights from TIMI frame count and TIMI myocardial perfusion grade. <i>Journal of Heart and Lung Transplantation</i> , <b>2007</b> , 26, 593-7	5.8	10

26	Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study). <i>American Journal of Cardiology</i> , <b>2006</b> , 97, 1553-7	3	59
25	Emerging role of intravascular ultrasound in the assessment of experimental anti-atherosclerotic therapies. <i>Current Medicinal Chemistry</i> , <b>2006</b> , 13, 1727-34	4.3	3
24	Intravascular ultrasound in cardiovascular medicine. <i>Circulation</i> , <b>2006</b> , 114, e55-9	16.7	44
23	Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. <i>JAMA - Journal of the American Medical Association</i> , <b>2006</b> , 295, 1556-65	27.4	1375
22	Determinants of arterial wall remodeling during lipid-lowering therapy: serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL) trial. <i>Circulation</i> , <b>2006</b> , 113, 2826-34	16.7	124
21	Effect of ACAT inhibition on the progression of coronary atherosclerosis. <i>New England Journal of Medicine</i> , <b>2006</b> , 354, 1253-63	59.2	319
20	Paradoxical increase in lumen size during progression of coronary atherosclerosis: observations from the REVERSAL trial. <i>Atherosclerosis</i> , <b>2006</b> , 189, 229-35	3.1	30
19	Intravascular ultrasound in the current percutaneous coronary intervention era. <i>Cardiology Clinics</i> , <b>2006</b> , 24, 163-73, v	2.5	7
18	Assessment of Progression and Regression of Coronary Atherosclerosis by Intravascular Ultrasound. A New Paradigm Shift?. <i>Revista Espanola De Cardiologia (English Ed)</i> , <b>2006</b> , 59, 57-66	0.7	
17	Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 992-7	15.1	136
16	Relationship between cardiovascular risk factors and atherosclerotic disease burden measured by intravascular ultrasound. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 47, 1967-75	15.1	127
15	Effects of normal, pre-hypertensive, and hypertensive blood pressure levels on progression of coronary atherosclerosis. <i>Journal of the American College of Cardiology</i> , <b>2006</b> , 48, 833-8	15.1	147
14	Simvastatin improves the attenuated heart rate recovery of type 2 diabetics. <i>Pharmacological Research</i> , <b>2006</b> , 54, 442-6	10.2	9
13	Intravascular ultrasound assessment of novel antiatherosclerotic therapies: rationale and design of the Acyl-CoA:Cholesterol Acyltransferase Intravascular Atherosclerosis Treatment Evaluation (ACTIVATE) Study. <i>American Heart Journal</i> , <b>2006</b> , 152, 67-74	4.9	26
12	Static and serial assessments of coronary arterial remodeling are discordant: an intravascular ultrasound analysis from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. <i>American Heart Journal</i> , <b>2006</b> , 152, 544-50	4.9	23
11	Compensatory enlargement of human coronary arteries during progression of atherosclerosis is unrelated to atheroma burden: serial intravascular ultrasound observations from the REVERSAL trial. <i>European Heart Journal</i> , <b>2006</b> , 27, 1664-70	9.5	25
10	The ACTIVATE study: lessons for the future of atherosclerotic therapy. <i>Future Lipidology</i> , <b>2006</b> , 1, 421-428		
9	Studying coronary plaque regression with IVUS. <i>Journal of Interventional Cardiology</i> , <b>2006</b> , 19, 345	1.8	1

8	Application of intravascular ultrasound in anti-atherosclerotic drug development. <i>Nature Reviews Drug Discovery</i> , <b>2006</b> , 5, 485-92	64.1	36
7	Recent trends in coronary intravascular ultrasound: tracking atherosclerosis, pursuit of vulnerable plaques, and beyond. <i>Journal of Nuclear Cardiology</i> , <b>2006</b> , 13, 91-6	2.1	5
6	LDL-cholesterol predicts negative coronary artery remodelling in diabetic patients: an intravascular ultrasound study. <i>European Heart Journal</i> , <b>2006</b> , 27, 1257; author reply 1257-8	9.5	
5	Coronary atherosclerosis can regress with very intensive statin therapy. <i>Cleveland Clinic Journal of Medicine</i> , <b>2006</b> , 73, 937-44	2.8	32
4	Plasma concentration of soluble vascular cell adhesion molecule-1 and oncoming cardiovascular risk in patients with unstable angina pectoris and non-ST-segment elevation myocardial infarction. <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 379-81	3	3
3	Effect of atorvastatin (80 mg/day) versus pravastatin (40 mg/day) on arterial remodeling at coronary branch points (from the REVERSAL study). <i>American Journal of Cardiology</i> , <b>2005</b> , 96, 1636-9	3	13
2	The changes in circulating levels of vasoactive intestinal polypeptide during exercise and its reproducibility for detection of myocardial ischemia. <i>International Heart Journal</i> , <b>2005</b> , 46, 363-71	1.8	2
1	Effect of quinapril on the attenuated heart rate recovery of type 2 diabetic subjects without known coronary artery disease. <i>Clinical Cardiology</i> , <b>2004</b> , 27, 480-4	3.3	2